In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and As…
The Trend of Advanced Systemic Treatments in the US and EU5
The use of advanced systemic treatments for managing debilitating diseases like systemic lupus erythematosus (SLE) has been on the rise in both the United States and the EU5 countries. However, recent data shows that the adoption of these treatments is higher in the US compared to the EU5.
Prior to the approval of Benlysta in 2011, patients and prescribers had limited options for treating SLE. Glucocorticoids were often the go-to treatment, despite their potential side effects and limitations. With the introduction of Benlysta and other advanced systemic treatments, there has been a shift in the treatment landscape.
The Growing Use of Benlysta in the US
In the United States, rheumatologists are increasingly turning to GSK’s Benlysta as a way to limit the use of glucocorticoids in SLE patients. Benlysta, which is the first FDA-approved treatment for SLE in over 50 years, has shown promising results in clinical trials. Its mechanism of action targets specific immune cells involved in the pathogenesis of SLE, providing a more targeted approach to treatment.
The use of Benlysta has been steadily increasing in the US, with more rheumatologists prescribing it to their patients. The goal is to reduce the reliance on glucocorticoids, which can have harmful long-term effects on patients. By turning to advanced systemic treatments like Benlysta, rheumatologists aim to improve the overall outcomes and quality of life for SLE patients.
Lagging Adoption in the EU5
In contrast, the adoption of advanced systemic treatments like Benlysta has been slower in the EU5 countries. Despite overall biologic growth in the region, there is still a reliance on traditional treatments like glucocorticoids. This disparity in adoption rates raises questions about the availability and accessibility of advanced treatments in different healthcare systems.
Efforts are being made to increase awareness and access to advanced systemic treatments in the EU5, with the hope of aligning with the trends seen in the US. As more data emerges on the effectiveness of treatments like Benlysta, it is likely that adoption rates will increase in the EU5 as well.
How This Trend Will Impact Individuals
For individuals living with conditions like SLE, the increasing use of advanced systemic treatments like Benlysta in the US means more treatment options and potentially better outcomes. By limiting the use of glucocorticoids, patients may experience fewer side effects and improved quality of life. It is important for patients to work closely with their healthcare providers to explore all treatment options available to them.
How This Trend Will Impact the World
On a global scale, the trend towards advanced systemic treatments in managing chronic diseases like SLE has the potential to improve healthcare outcomes for populations worldwide. As more countries adopt these treatments and shift away from traditional approaches, there is an opportunity to reduce disease burden and improve overall health outcomes. This shift underscores the importance of continued research and innovation in the field of biologic treatments.
Conclusion
The increasing use of advanced systemic treatments like Benlysta in the US, compared to the EU5, highlights the evolving landscape of healthcare and treatment options for patients with chronic diseases. By prioritizing targeted and effective treatments over traditional approaches, healthcare providers are striving to improve outcomes and quality of life for patients. As awareness grows and access increases, the impact of these trends has the potential to positively influence healthcare systems around the world.
